Announcement of Grant Award from NEDO

 We are pleased to announce that Optieum Biotechnologies Inc. has been awarded “NEDO STS” grant from New Energy and Industrial Technology Development Organization (NEDO).

 This grant was submitted with the support of ANRI, a venture capital. With this funding, we will continue to expand our platform technology and accelerate the development of in-house CAR-T cell programs.

 We are committed to go beyond the limits of immuno-oncology drug development and deliver the most appropriate treatment for the cancer patients in needs.